Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon May 29, 2020 1:09am
349 Views
Post# 31086028

Time line has changed

Time line has changed first thing that popped out was this new time line...it appears that up a few items from previous time lines.have suddenly been bumped up . I sense a real positive momentum building right now... this means something big has to be coming and I think there are people out there getting the same feeling.. a good signal could be that a indiv indicating that he is a NY trader /banker has just mentioned that he thinks something big is about to happen... this isn't just us regulars sitting at the Tims .. this is someone out of our usual circle and someone that has no respect for our present management but he thinks something is going to happen ..I wonder what is coming out next...

Significant Event Timeline

ProMIS has a number of recent and upcoming milestones related to development of its pipeline which we summarize below.

Confidential discussions with potential partners for platform programs - Ongoing

PMN310 scale up manufacturing – 2019

Capital raise or partnership to fund entry into clinic – 2020

Prepare IND and Phase I trial for PMN310 – 2020

Pursue a vectorization deal - 2020

Generate Phase I biomarker data with Toronto Memory Program – 2020

Launch Phase I trial in PMN310 - 2021 

 
Bullboard Posts